In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors1Presented in part at the `9th ECNP Congress', Amsterdam, September 21–25, 1996 (Ahlenius et al., 1996).1-Reference-Cited by-同舟云学术

In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors1Presented in part at the `9th ECNP Congress', Amsterdam, September 21–25, 1996 (Ahlenius et al., 1996).1

Published:1999-01 Issue:1-2 Volume:9 Page:15-19
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Ahlenius Sven,Henriksson Ingrid,Magnusson Olle,Salmi Peter

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology

Reference38 articles.

1. Aghajanian, G.K., 1995. Electrophysiology of serotonin receptor subtypes and signal transduction pathways. In: Bloom, F.E., Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 451–460..

2. Dopaminergic properties of the 5-HT1A receptor antagonists WAY-100,635 and (S)-UH-301;Ahlenius;Eur. Neuropsychopharmacol.,1996

3. Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat;Ahlenius;Naunyn-Schmiedeberg's Arch. Pharmacol.,1989

4. Increased dopamine turnover in the ventral striatum by 8-OH-DPAT administration in the rat;Ahlenius;J. Pharm. Pharmacol.,1990

5. Andén, N.-E., 1980. Regulation of monoamine synthesis and utilization by receptors. In: Szekeres, L. (Ed.), Handbook of Experimental Pharmacology. Springer-Verlag, Berlin-Heidelberg, pp. 429–462.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output;Psychopharmacology;2014-01-14

2. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders;Chemical Reviews;2013-05-08

3. Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease;Journal of Neural Transmission;2011-01-21

4. Regulation of conditioned and unconditioned fear in rats by 5-HT1A receptors in the dorsal periaqueductal gray;Pharmacology Biochemistry and Behavior;2008-03

5. The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy;Pharmacology Biochemistry and Behavior;2007-08